On May 9, 2023, Gilead Sciences announced the acquisition of San Diego-based XinThera, a privately held biotech company. The acquisition will give Gilead rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Wilson Sonsini Goodrich & Rosati advised XinThera on the transaction.

XinThera was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D. and is backed by a group of investors, including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. Financial terms were not disclosed.

The Wilson Sonsini team that advised XinThera includes:

M&A
Rob Ishii
Jason Breen
David Adler
Ryan Cooper
Cindy West

Technology Transactions
Miranda Biven
Lauren Wardle
Sai Upadhyayula
Aleksandar Vitomirov

Patents
Michael Hostetler
Uale Taotafa
Celine Bonnefous

Privacy
Matthew Staples
Daniel Chen

Labor
Rebecca Stuart
Allison Ivey Toth

Tax
Myra Sutanto Shen
Anthony Yanez

Benefits
Michelle Wallin
Gregory Hughes

Regulatory
Eva Yin

Antitrust
Michelle Hale
Kimberly Biagioli

For more information, please view the press release.